LumiraDx Receives UK MHRA Approval for SARS-CoV-2 RNA STAR Complete

February 21, 2022 (London): LumiraDx (Nasdaq: LMDX) announced today that its rapid COVID-19 molecular assay, LumiraDx SARS-CoV-2 RNA STAR Complete, has been successfully validated by Coronavirus Test Device Approvals (CTDA) and received UK Medicines and Healthcare products Regulatory Agency (MHRA) approval. LumiraDx SARS-CoV-2 RNA STAR Complete, developed with proprietary qSTAR technology,...

Translate »
topbar-lumiradx-popup
Estás apunto de ser redirigido a
www.lumiradx.com/uk-en/